Financials · ANGO

AngioDynamics Inc. (ANGO) financials

For the twelve months ended Aug 31, 2026, AngioDynamics Inc. reported $325.38M of revenue and -$32.94M of net income.

Revenue, TTM
$325.38M
Revenue growth, YoY
+8.2%
Net income, TTM
-$32.94M
Net margin
-10.1%
Free cash flow, TTM
$1.44M
EPS, diluted, TTM
-$0.79
Cash
$33.97M
P/S
1.56
Market cap
$507.6M
Annual revenue$320.17M
FY2017FY2026
Annual net income-$36.74M
FY2017FY2026
Annual free cash flow$508.0K
FY2017FY2026

ANGO revenue and earnings growth

ANGO revenueQ1 2027$80.92M

Quarter YoY
+6.9%
QoQ
-6.6%
FY YoY
+9.5%
5Y CAGR
+1.9%
10Y CAGR
-1.0%

ANGO revenue was $80.92M in fiscal Q1 2027 (ended Aug 31, 2026), up 6.9% from a year earlier and down 6.6% from the prior quarter. For the full fiscal 2026 it was $320.17M, up 9.5% from fiscal 2025. Compound annual growth was +1.9% over 5 years and -1.0% over 10 years. It rose in 5 of the last 10 fiscal years.

ANGO net incomeQ1 2027-$7.10M

ANGO net income was -$7.10M in fiscal Q1 2027 (ended Aug 31, 2026), compared with -$10.90M a year earlier. For the full fiscal 2026 it was -$36.74M, compared with -$33.99M in fiscal 2025.

ANGO EPSQ1 2027-$0.17

ANGO diluted EPS was -$0.17 in fiscal Q1 2027 (ended Aug 31, 2026), compared with -$0.26 a year earlier. For the full fiscal 2026 it was -$0.88, compared with -$0.83 in fiscal 2025.

ANGO free cash flowQ1 2027-$15.71M

5Y CAGR
-51.5%
10Y CAGR
-35.8%

ANGO free cash flow was -$15.71M in fiscal Q1 2027 (ended Aug 31, 2026), compared with -$16.64M a year earlier. For the full fiscal 2026 it was $508.0K, compared with -$14.59M in fiscal 2025. Compound annual growth was -51.5% over 5 years and -35.8% over 10 years.

Export CSV

Income statement

Income statement
Line item
May 31, 2026
May 31, 2025
May 31, 2024
May 31, 2023
May 31, 2022
May 31, 2021
May 31, 2020
May 31, 2019
May 31, 2018
May 31, 2017
Revenue$320.17M$292.50M$303.91M$338.75M$316.22M$291.01M$264.16M$270.63M$261.65M$269.79M
Cost of revenue$145.28M$134.79M$149.22M$164.51M$150.49M$134.22M$113.89M$114.63M$117.80M$125.84M
Gross profit$174.89M$157.71M$154.70M$174.25M$165.73M$156.79M$150.27M$156.00M$143.86M$143.95M
Research and development$29.45M$26.22M$31.51M$29.88M$30.74M$36.39M$29.68M$28.26M$24.34M$24.15M
Selling, general and admin$43.69M$42.09M$41.16M$40.00M$38.45M$35.92M$37.87M$34.90M$30.99M$31.13M
Operating income-$39.93M-$39.95M-$192.44M-$51.18M-$28.47M-$35.28M-$167.10M-$9.40M-$14.17M-$11.18M
Interest expense---$1.61M$2.70M$688.0K$861.0K$907.0K$5.10M$3.06M$2.84M
Pre-tax income-$36.30M-$34.03M-$191.64M-$54.44M-$29.95M-$36.05M-$168.13M-$14.70M-$17.26M-$14.29M
Income tax$442.0K-$39.0K-$7.29M-$2.00M-$3.40M-$4.50M-$1.35M-$3.56M-$11.04M-$7.24M
Net income-$36.74M-$33.99M-$184.35M-$52.44M-$26.55M-$31.55M-$166.79M$61.34M$16.34M$5.01M
EPS, basic-$0.88-$0.83-$4.59-$1.33-$0.68-$0.82-$4.39$1.64$0.44$0.14
EPS, diluted-$0.88-$0.83-$4.59-$1.33-$0.68-$0.82-$4.39$1.64$0.44$0.14
Diluted shares41.5M40.9M40.2M39.5M39.0M38.3M38.0M37.5M37.1M36.6M

Balance sheet

Balance sheet
Line item
May 31, 2026
May 31, 2025
May 31, 2024
May 31, 2023
May 31, 2022
May 31, 2021
May 31, 2020
May 31, 2019
May 31, 2018
May 31, 2017
Cash and equivalents$53.86M$55.89M$76.06M$44.62M$28.82M$48.16M$54.44M$227.64M$74.10M$47.54M
Receivables$48.33M$42.89M$43.61M$52.83M$52.30M$35.41M$31.26M$43.58M$39.40M$44.52M
Inventory$52.44M$62.01M$60.62M$55.33M$51.39M$48.61M$59.91M$40.07M$39.27M$54.51M
Current assets$163.39M$168.32M$193.25M$163.54M$143.34M$140.88M$152.91M$315.29M$168.03M$153.91M
Goodwill--$0$159.24M$201.06M$201.32M$200.51M$347.67M$285.94M$361.25M
Total assets$267.16M$280.14M$317.67M$532.64M$552.75M$561.44M$594.21M$836.44M$705.47M$707.96M
Current liabilities$74.72M$76.20M$91.16M$83.83M$74.32M$57.58M$51.45M$73.30M$57.30M$71.52M
Short-term debt------$0$7.50M$5.00M$5.00M
Long-term debt-------$124.41M$86.62M$91.32M
Total debt--$0$49.82M$25.00M--$131.91M$91.62M$96.32M
Total liabilities$96.34M$97.17M$112.08M$154.34M$128.26M$121.98M$139.34M$221.62M$162.88M$192.93M
Shareholders' equity$170.82M$182.97M$205.59M$378.30M$424.49M$439.46M$454.87M$614.82M$542.60M$515.03M

Cash flow

Cash flow
Line item
May 31, 2026
May 31, 2025
May 31, 2024
May 31, 2023
May 31, 2022
May 31, 2021
May 31, 2020
May 31, 2019
May 31, 2018
May 31, 2017
Operating cash flow$3.09M-$10.13M-$28.16M$78.0K-$7.19M$24.09M-$14.55M$37.44M$41.29M$55.74M
Capital expenditures$2.58M$4.46M$2.52M$3.81M$4.30M$5.19M$7.24M$3.12M$2.39M$3.00M
Free cash flow$508.0K-$14.59M-$30.68M-$3.73M-$11.49M$18.91M-$21.79M$34.32M$38.90M$52.74M
Investing cash flow-$5.95M-$10.18M$123.72M-$9.75M-$19.31M-$13.71M-$63.34M$82.55M-$3.66M-$2.55M
Financing cash flow$564.0K-$255.0K-$64.25M$25.42M$7.68M-$16.99M-$95.24M$33.93M-$11.55M-$37.98M
Share repurchases$0$1.67M$0$0---$0$0$13.56M
Stock-based compensation$13.96M$9.77M$10.53M$11.16M$10.69M$8.63M$7.59M$9.25M$7.91M$6.18M
Depreciation and amortization$22.95M$25.80M$27.71M$30.87M$29.35M$25.92M$23.80M$25.88M$23.16M$24.81M

Key ratios

Key ratios
Line item
May 31, 2026
May 31, 2025
May 31, 2024
May 31, 2023
May 31, 2022
May 31, 2021
May 31, 2020
May 31, 2019
May 31, 2018
May 31, 2017
Revenue growth, YoY9.5%-3.8%-10.3%7.1%8.7%10.2%-2.4%3.4%-3.0%-23.8%
Net income growth, YoY-------275.5%226.2%-
EPS growth, YoY-------272.7%214.3%-
Gross margin54.6%53.9%50.9%51.4%52.4%53.9%56.9%57.6%55.0%53.4%
Operating margin-12.5%-13.7%-63.3%-15.1%-9.0%-12.1%-63.3%-3.5%-5.4%-4.1%
Net margin-11.5%-11.6%-60.7%-15.5%-8.4%-10.8%-63.1%22.7%6.2%1.9%
Free cash flow margin0.2%-5.0%-10.1%-1.1%-3.6%6.5%-8.2%12.7%14.9%19.6%
Return on equity-21.5%-18.6%-89.7%-13.9%-6.3%-7.2%-36.7%10.0%3.0%1.0%
Return on assets-13.8%-12.1%-58.0%-9.8%-4.8%-5.6%-28.1%7.3%2.3%0.7%
Current ratio2.192.212.121.951.932.452.974.302.932.15
Debt to equity--0.000.130.06--0.210.170.19

Source: XBRL data AngioDynamics Inc. files with the SEC, latest filing dated Oct 8, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

ANGO peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
ANGO$325.38M+8.2%-$32.94M-10.1%$507.6M
SYK$26.30B+7.9%$3.62B13.8%$123.45B
MMM$25.25B+1.7%$3.54B14.0%$97.85B
BSX$21.07B+8.9%$3.50B16.6%$64.78B
BDX$23.25B+17.4%$941.00M4.0%$57.91B
MDLN$30.68B-$683.00M2.2%$53.81B
RMD$5.73B+9.0%$1.59B27.8%$32.93B
DXCM$5.10B+13.0%$991.00M19.4%$29.81B
WST$3.40B+12.6%$638.90M18.8%$28.74B

ANGO FAQ

9 questions
  • What is ANGO revenue?
    AngioDynamics Inc. (ANGO) reported $325.38M of revenue for the twelve months ended Aug 31, 2026. That is up 8.2% from the year before. Revenue for fiscal 2026 was $320.17M.
  • Is ANGO profitable?
    No. AngioDynamics Inc. reported a net loss of $32.94M for the twelve months ended Aug 31, 2026.
  • How much cash and debt does ANGO have?
    AngioDynamics Inc. reported $33.97M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is ANGO revenue growing?
    AngioDynamics Inc.'s revenue changed +9.5% in fiscal 2026, to $320.17M. Its compound annual growth rate was +1.9% over 5 years and -1.0% over 10 years.
  • What is ANGO gross margin?
    AngioDynamics Inc.'s gross profit was $181.07M on $325.38M of revenue for the twelve months ended Aug 31, 2026, a gross margin of 55.7%.
  • What is ANGO free cash flow?
    AngioDynamics Inc. generated $1.44M of free cash flow for the twelve months ended Aug 31, 2026, which is operating cash flow of $3.67M less capital expenditures.
  • What is ANGO earnings per share?
    Diluted earnings per share were -$0.79 for the twelve months ended Aug 31, 2026, from SEC filings, restated for any stock split those filings show.
  • When did ANGO last report financial results?
    The latest statements here come from AngioDynamics Inc.'s 10-Q filed on Oct 8, 2026, covering the period ended Aug 31, 2026.
  • Where does this ANGO financial data come from?
    Quantisnow builds these statements from the structured XBRL data AngioDynamics Inc. files with the SEC. It is provided for information only and is not investment advice.